Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma

Tingting Liu, Matthew D. Merguerian, Steven P. Rowe, Christine A. Pratilas, Allen R. Chen, Brian H. Ladle

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds